Pluvicto
Radioligand Patient Information Video
What you need to know before, during, and after treatment.
New Targeted Therapy for Prostate Cancer Now Available at UF Health Radiation Oncology – Davis Cancer Pavilion
Pluvicto, a targeted therapy for progressive, PSMA-positive metastatic castration-resistant prostate cancer, has been approved for clinical use by the FDA. On April 26, UF Health Radiation Oncology became the first in the state of Florida to administer it to patients.* Pluvicto is a next generation radioligand treatment…
Systemic Radioisotope Therapy
PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)* PLUVICTO is radiopharmaceutical used to treat adults with advanced prostate cancer that is prostate-specific membrane antigen–Âpositive (PSMA-positive), metastatic and castration-resistant (mCRPC). PSMA-positive prostate cancers can be detected by a special PET scan. PLUVICTO is a treatment option for PSMA-positive mCRPC that…
